Company Profile
Aldeyra Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- ALDX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.59 USD (-0.63%)
Close
Last updated: August 6, 2026
98.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ALDX closed down 0.63% at $1.59. No new same-company headline was identified in the current news window.
Company overview
Business overview
Aldeyra Therapeutics is a biotechnology company focused on inflammation, ophthalmology, and immune-mediated disease. Its story is built around therapies for conditions where inflammation plays a major role.
Geographic Base and Sector Classification
Aldeyra is headquartered in the United States and listed on NASDAQ. It sits in specialty immunology and ophthalmology biotechnology.
Business Model Characteristics
The company depends on clinical data, regulatory progress, and the ability to develop a focused pipeline in challenging inflammatory diseases. Investors usually watch efficacy, safety, and approval milestones.
Position Within the Biotechnology Landscape
Aldeyra occupies a niche inflammation-and-eye-disease position within biotech. The stock is catalyst-sensitive because a narrow number of data events can meaningfully shift the story.
Future catalysts
Aldeyra’s catalysts are reproxalap and the dry-eye / ophthalmology regulatory path, where the next step can materially move the stock. The company is still very event-driven.
Recent news
- 01
- 02
Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results
Source: Aldeyra Therapeutics, Inc.
- 03
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
Source: Aldeyra Therapeutics, Inc.
- 04
Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
Source: Aldeyra Therapeutics, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aldeyra Therapeutics, Inc. (ALDX)?
Aldeyra Therapeutics, Inc. (ALDX) most recently closed at 1.59 USD, a -0.63% move versus the previous session.
What is the market cap of Aldeyra Therapeutics, Inc. (ALDX)?
Aldeyra Therapeutics, Inc. currently has a market capitalization of 98.9M USD on BioPharmSignal.
What does Aldeyra Therapeutics, Inc. do?
Aldeyra Therapeutics is a biotechnology company focused on inflammation, ophthalmology, and immune-mediated disease. Its story is built around therapies for conditions where inflammation plays a major role.
On which exchange is ALDX stock listed?
Aldeyra Therapeutics, Inc. (ALDX) is associated with NASDAQ, United States, Biopharma.
What is Aldeyra?
Aldeyra’s catalysts are reproxalap and the dry-eye / ophthalmology regulatory path, where the next step can materially move the stock.
Which conditions is Aldeyra Therapeutics, Inc. targeting with Aldeyra?
Aldeyra Therapeutics, Inc. is associated with inflammatory disease, ophthalmology based on its company overview and current catalyst commentary.
How does Aldeyra Therapeutics, Inc. describe recent progress with Aldeyra?
Aldeyra’s catalysts are reproxalap and the dry-eye / ophthalmology regulatory path, where the next step can materially move the stock.
What is Therapeutics?
Aldeyra Therapeutics is a biotechnology company focused on inflammation, ophthalmology, and immune-mediated disease.